Filing summary
Entity note: The supplied filing is Conduit Pharmaceuticals Inc. (Nasdaq: CDT), not a company named CDT Equity Inc. It is a Form 10-K for the fiscal year ended December 31, 2023, filed April 16, 2024. The business combination with Murphy Canyon Acquisition Corp. closed September 22, 2023; the statements reflect a reverse recapitalization.
Business context and reporting period
Conduit is a clinical-stage biopharmaceutical company with no approved products or meaningful product revenue. It aims to advance licensed or internally developed assets through Phase II, then seek licensing or other partnerships for later development and commercialization. Its lead programs include AZD1656 for autoimmune and other indications, AZD5904 for idiopathic male infertility, and a company-owned, patent-pending AZD1656 cocrystal. The company had seven full-time employees and two consultants at year-end.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $90,000 | $37,000 |
| General and administrative expense | $5.172 million | $3.049 million |
| Operating loss | $5.262 million | $3.160 million |
| Other income (expense), net | $4.727 million income | $1.727 million expense |
| Net loss | $535,000 | $4.887 million |
| Cash used in operating activities | $7.725 million | $2.266 million |
Margins are not meaningful because the company reported no product revenue. The lower 2023 net loss, despite a larger operating loss, was driven substantially by non-operating, noncash accounting items, including gains and deferred-income recognition associated with the Vela and Cizzle arrangements. The filing reports diluted net loss of $6.056 million, or $0.09 per share, after an adjustment related to option liabilities; basic net loss was $0.01 per share.
At December 31, 2023, cash and cash equivalents were $4.228 million, current assets $5.733 million, current liabilities $1.801 million, total assets $7.224 million, and total liabilities $7.681 million. Stockholders’ deficit was $457,000. Total liabilities included a $5.738 million deferred commission payable to the merger advisor, due no later than March 21, 2025, with 5.5% annual interest. Current obligations included an $800,000 convertible promissory note bearing 20% annual interest and notes payable with a reported current portion of $185,000.
Operating cash outflow rose year over year despite the smaller net loss. Financing activities provided $10.929 million in 2023, including $8.493 million of net proceeds from the merger and PIPE financing and $2.286 million from convertible promissory notes. The PIPE raised $20 million gross; net proceeds from the merger and PIPE after transaction costs and other payments were reported as $8.5 million.
Changes versus the prior comparable period
- Operating loss increased from $3.160 million to $5.262 million, with general and administrative expense up 70%, primarily reflecting higher professional fees, payroll and stock compensation, travel, and insurance.
- Research and development expense rose from $37,000 to $90,000, mainly for development of AZD1656 cocrystals. No project funding expense was recorded in 2023, compared with $74,000 in 2022.
- Net loss narrowed from $4.887 million to $535,000, but the change reflects non-operating items rather than improved operating performance.
- Cash used in operations increased to $7.725 million from $2.266 million. Year-end cash increased from zero to $4.228 million, largely following merger-related financing.
- The company restated previously issued 2023 quarterly financial statements after determining merger-related legal costs should have been capitalized as transaction costs rather than expensed. The filing says the errors were material to the affected periods.
Outlook, risks, contingencies, and unusual items
- Going concern: Management and the auditor identify substantial doubt about the company’s ability to continue as a going concern for at least 12 months from the financial statement issuance date. Management says additional funding is needed and is not assured. A $5 million working-capital commitment from major shareholder Corvus Capital was subject to agreement and definitive documentation; a later commitment letter provides for draws and 9.5% annual interest.
- Development plans: Management intends to pursue selected clinical programs, generally through Phase II, then seek a partner. Plans include Phase II studies of AZD1656 in several indications and an AZD5904 Phase Ib proof-of-mechanism study before Phase II. The company had not decided whether to fund any of the five St George Street project agreements. No trial success, regulatory approval, monetization, or revenue is assured.
- Clinical and commercial risks: Prior AstraZeneca studies may not satisfy FDA requirements, and additional trials could be needed. The company relies on third-party CROs, manufacturers, suppliers, and license arrangements, including a chain of rights through St George Street and AstraZeneca. It has no in-house manufacturing or sales infrastructure.
- Financial reporting controls: Material weaknesses remain in internal control over financial reporting, including limited segregation of duties, inadequate review and monitoring controls, and prior recurring reporting errors. Remediation was underway but not complete. The company also reports quarterly restatements of 2023 statements.
- Legal contingency: Strand Hanson claims $2 million in advisory fees and 6.5 million shares. Conduit disputes the claim and intends to defend it. Management said the outcome could not yet be evaluated; no loss contingency was accrued because it was not considered probable or reasonably estimable.
- Ownership and dilution: Corvus Capital, Algo Holdings, and Andrew Regan collectively beneficially owned approximately 61.8% of common stock as of April 16, 2024. The company is a Nasdaq “controlled company,” and its equity plan allows substantial additional share issuance. Potential warrants and equity awards could also dilute shareholders.
- Other unusual items: Vela and Cizzle exercised options to exchange their future-revenue interests in AZD1656 for company shares, resulting in recognition of deferred income and fair-value gains. The filing reports 73,829,536 common shares outstanding as of April 16, 2024.
Most important facts for investors to verify
- Whether the conditional $5 million Corvus funding commitment was finalized, drawn, and sufficient to fund operations, and the company’s cash runway and near-term funding needs.
- The amount and timing of obligations, particularly the 20% convertible note, notes payable, and $5.738 million deferred advisor commission plus interest.
- Progress, funding decisions, trial start dates, enrollment, and regulatory requirements for AZD1656 and AZD5904; also confirm which historical trial data regulators will accept.
- Whether internal-control weaknesses have been remediated and whether any further financial-statement corrections are required.
- Developments in the Strand Hanson litigation and any resulting cash, share, or other liability exposure.
- The terms and potential dilution from outstanding warrants, equity-plan awards, and any future financing.